Wegovy, made by drug manufacturer Novo Nordisk, is a brand-name, injectable medication containing the active ingredient semaglutide
placebo on vascular inflammation in 102 patients with T2D over 26 weeks as assessed by fluorodeoxyglucose-positron emission tomography/computed tomography (primary outcome), and also to evaluate endothelial function, coronary artery calcium, and carotid-intima thickness (56)
J Leukoc Biol 80:10671075 Gras G, Samah B, Hubert A et al (2011) EEAT expression by macrophages and microglia: still more question than answers
Recently, interest has emerged regarding whether GLP-1 medications might help with attention deficit hyperactivity disorder (ADHD) symptoms, given that GLP-1 receptors are present in brain regions involved in attention and impulse control
Peptides and HRT: Can They Be Combined
2021;70:673-P